Aptamer-based diagnostic platform granted US Patent
Search jobs
Aptamer-based diagnostic platform granted US Patent
- The first use of aptamers to detect viruses and other pathogens.
- The platform provides a basis for an accurate COVID-19 test.
Montreal (QC), April 22, 2021 – Two-Photon Research announces the grant of a patent “
Pathogen Detection Using Aptamer Molecular Beacons Using a Mobile Device” by the US Patent and Trademark Office (patent no. US 10,927,404 B1). The patent was awarded within sixty days of the application.
The invention is based on the field of aptamers, short molecules complementary to the protein and other molecular sequences, that are well suited for finding and binding to target sequences with very high specificity and affinity.
Physiker erzeugen Milliarden einzelner Photonen onlinepc.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onlinepc.ch Daily Mail and Mail on Sunday newspapers.
Dec 14, 2020
Montreal-based Two-Photon Research has announced CAST, a diagnostics platform that changes the way viruses are detected.
The CAST platform uses TPR’s patented Aptamer Molecular Photonic Beacon (AMPB) that photonically interfaces with smartphones.
The first application of CAST is for detecting SARS-CoV-2 to help control the Covid-19 pandemic.
During the test, the AMPB binds to the S1 protein of SARS-CoV-2 if it is present in the saliva sample. On binding with the S1 protein, the AMPB responds to the smartphone’s LED flash. The light emitted by the AMPB is then detected by the smartphone’s CMOS sensors. No photons, no virus.